JZ
Therapeutic Areas
Novita Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| NP-G2-044 | Advanced/Metastatic Solid Tumor Malignancies (Monotherapy) | Phase 2a |
| NP-G2-044 + anti-PD-1 Inhibitors | Solid Tumors | Phase 2a |
| NP-G2-044 + Chemotherapy Agents | Ovarian Cancer | Phase 2a |
Leadership Team at Novita Pharmaceuticals
SC
Stewart Campbell
Chief Executive Officer, Board Member
CY
Christy Y. Shue
Chief Financial Officer
XH
Xin-Yun Huang
Co-Founder